Nav: Home

Should patients be allowed to opt out of routine genetic testing of colorectal tumors?

October 06, 2016

TORONTO, Oct. 6, 2016--Health-care providers support routine testing of colorectal tumours to identify more individuals who have the most common genetic condition responsible for such cancers, a new study suggests.

And few felt patients should have the right to opt out of this test that would determine whether they have Lynch Syndrome, according to the study by Dr. Yvonne Bombard, a genomics and health services researcher in the Li Ka Shing Knowledge Institute of St. Michael's Hospital.

The study was published online today in the journal Genetics in Medicine.

Lynch Syndrome, which is caused by defects in four genes, accounts for about three to five per cent of colorectal colon cancer cases. People who carry those mutations are at an increased lifetime risk of several cancers, including a 12-48 per cent risk of colorectal cancer and a 15-54 per cent risk of endometrial cancer. Early detection and monitoring can reduce the incidence of colorectal cancer: when detected early, as Stage 1 colorectal cancer, an estimated 90 per cent of people will survive.

Dr. Bombard interviewed surgeons, genetic counselors, oncologists, primary care physicians and gastroenterologists for their views and experiences on tumor testing, notification of results, counseling patients with Lynch Syndrome and their families, and their vision for the design and implementation of routine testing.

The medical profession has been divided over the need for explicit patient consent to test tumours for Lynch Syndrome. Those who opposed allowing patients to opt out of routine testing said it was akin to other pathology tests, which are not optional, and would help identify and manage more Lynch Syndrome patients and their relatives who might also be at risk.

Those who supported allowing patients to opt out of routine testing of their colorectal tumours referred to the need to protect the few patients who would receive positive results and may suffer distress or insurance discrimination, versus the need to avoid causing unnecessary anxiety to the majority of patients who would screen negative. Also at issue are the significant resources and expertise required to obtain consent.

Once suspected Lynch Syndrome patients were identified, providers also worried about long wait times to get appointments with genetic counselors and about regional variation in access to counselors.

"Providers emphasized that the introduction of routine testing alone would not necessarily improve care overall for Lynch Syndrome patients and their families," Dr. Bombard said. "They felt that a comprehensive approach was needed to increase awareness of Lynch Syndrome in the wider medical community and that substantial change would need to occur to improve coordinated care, adequate resourcing for genetic services and ongoing surveillance, and provider awareness and education of Lynch Syndrome."

There are limitations to the study: the researchers interviewed a small number of providers. Dr. Bombard said patients' views were also needed to ensure that their preferences were incorporated into the design of any program.

"Many health-care systems are considering implementing routine testing for Lynch Syndrome for patients with cancer to improve identification of families at high risk of developing colorectal cancer for more intensive screening," said Dr. Nancy Baxter, chief of the General Surgery Department at St. Michael's and one of the paper's co-authors. "This research will help guide how these programs should be developed."
This study received funding from Cancer Care Ontario and the Ontario Institute for Cancer Research.

About St. Michael's Hospital

St. Michael's Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future health care professionals in more than 23 academic disciplines. Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, and care of the homeless are among the Hospital's recognized areas of expertise. Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Center, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael's Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto.

For more information or to arrange an interview with Dr. Bombard, please contact:

Leslie Shepherd
Manager, Media Strategy
Phone: 416-864-6094
St. Michael's Hospital
Inspired Care. Inspiring Science.
Follow us on Twitter:

St. Michael's Hospital

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...